PMID- 21717592
OWN - NLM
STAT- MEDLINE
DCOM- 20120215
LR  - 20111215
IS  - 1934-6638 (Electronic)
IS  - 1934-662X (Linking)
VI  - 119
IP  - 6
DP  - 2011 Dec 25
TI  - A multicolor fluorescence in situ hybridization assay: A monitoring tool in the 
      surveillance of patients with a history of non-muscle-invasive urothelial cell 
      carcinoma: A prospective study.
PG  - 395-403
LID - 10.1002/cncy.20168 [doi]
AB  - BACKGROUND: Non-muscle-invasive urothelial cell carcinoma (NMIUCC) has a high 
      tendency to recur and affected patients must be monitored regularly using 
      invasive cystoscopies. The aim of the current study was to compare a multicolor 
      fluorescence in situ hybridization (FISH) assay (UroVysion) with routine 
      follow-up (cystoscopy and cytology) in the monitoring of patients with a previous 
      history of NMIUCC. METHODS: An unselected cohort of patients under surveillance 
      for a previous history of NMIUCC was prospectively studied. A total of 248 
      examinations in 223 patients were analyzed. Each exploration was comprised of 
      cytological and FISH microscopic examination of voided urine samples and 
      cystoscopy. The sensitivity, specificity, and positive (PPV) and negative (NPV) 
      predictive values for tumor recurrence of all 3 techniques were determined. 
      RESULTS: The sensitivities of FISH and cystoscopy were not found to be 
      significantly different (92.9% and 82.1%, respectively). The specificities of 
      FISH and cystoscopy were 92.7% and 89.7%, respectively. The PPV and NPV of FISH 
      were 53.5% and 97.2%, respectively, whereas those of cystoscopy were 63.4% and 
      98.9%, respectively. No significant differences were found between these 2 tests. 
      In contrast, the sensitivity and specificity of cytology were 14.3% and 99.5%, 
      respectively. CONCLUSIONS: Given the lack of statistically significant 
      differences with regard to FISH and cystoscopy results, the authors propose that 
      FISH could be a useful monitoring tool in the surveillance of patients with a 
      previous history of NMIUCC.
CI  - Copyright (c) 2011 American Cancer Society.
FAU - Galvan, Ana B
AU  - Galvan AB
AD  - Molecular Cytogenetics Laboratory, Department of Pathology, Hospital del Mar 
      Research Institute, Barcelona, Spain.
FAU - Salido, Marta
AU  - Salido M
FAU - Espinet, Blanca
AU  - Espinet B
FAU - Placer, Jose
AU  - Placer J
FAU - Pijuan, Lara
AU  - Pijuan L
FAU - Juanpere, Nuria
AU  - Juanpere N
FAU - Lloreta, Josep
AU  - Lloreta J
FAU - Sole, Francesc
AU  - Sole F
FAU - Gelabert-Mas, Antoni
AU  - Gelabert-Mas A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110629
PL  - United States
TA  - Cancer Cytopathol
JT  - Cancer cytopathology
JID - 101499453
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Carcinoma in Situ/diagnosis/pathology/urine
MH  - Cohort Studies
MH  - Cytological Techniques/methods
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Recurrence
MH  - Sensitivity and Specificity
MH  - *Urinary Bladder Neoplasms/diagnosis/pathology/urine
EDAT- 2011/07/01 06:00
MHDA- 2012/02/16 06:00
CRDT- 2011/07/01 06:00
PHST- 2011/01/07 00:00 [received]
PHST- 2011/04/14 00:00 [revised]
PHST- 2011/04/19 00:00 [accepted]
PHST- 2011/07/01 06:00 [entrez]
PHST- 2011/07/01 06:00 [pubmed]
PHST- 2012/02/16 06:00 [medline]
AID - 10.1002/cncy.20168 [doi]
PST - ppublish
SO  - Cancer Cytopathol. 2011 Dec 25;119(6):395-403. doi: 10.1002/cncy.20168. Epub 2011 
      Jun 29.